



BeiGene

Nominated by Karen Carr, Senior Director, Field HEOR, BeiGene

Innovation and Leadership

BeiGene is a global oncology company focused on delivering innovative medicines faster, more equitably and affordably to more patients around the world. We believe that all patients deserve access to high-quality, innovative, and impactful medicines, regardless of their location or socioeconomic status. As we work to provide treatments to patients worldwide, we also strive to support their families, caregivers, and the advocacy organizations who act on their behalf. Our values and mission drive us to elevate patient voices, engage in the community, and evolve the global health conversation to improve patient care.

Our entrepreneurial culture is designed for speed to meet the urgent needs in cancer, and we have more than 10,000 colleagues working relentlessly across five continents for patients. A feature that makes BeiGene unique compared to other pharmaceutical companies is its differentiated in-house model, comprising the following:

- One of the largest oncology research teams in the world, with more than 1,100 highly credentialed scientists with a proven track record of developing innovative medicines that address significant unmet needs.
- A globally inclusive clinical development team driving trial innovation in underrepresented countries by conducting clinical trials, largely free of contract research organizations (CROs). Conducting clinical trials in-house rather than outsourcing to a CRO allows BeiGene to develop more effective collaborations with clinical trial sites, enroll patients faster, accelerate clinical development, and improve quality.
- A commercial strategy that brings innovative, high-quality therapies to the greatest number of patients as quickly as possible. We actively seek to build collaborations with health systems to accelerate our medicines' availability to patients worldwide.
- In just over a decade, our differentiated model has allowed us to generate more potential groundbreaking molecules in less time and receive regulatory approvals in 70 markets across three internally developed medicines.

Cost Management

The myBeiGene® patient support program, currently available in the U.S. and Canada, provides support for prescribed patients through personalized assistance from a dedicated Oncology Nurse Advocate. A team of dedicated and experienced oncology nurses act as the point of contact for patients and caregivers for all hub services, which include benefit investigation, bridge support, patient assistance product, and other services to ensure BeiGene is addressing each patient's needs. As the landscape shifts, BeiGene continues to put the patient first by offering an inclusive Patient Assistance Program criteria that considers that many patients struggle to afford care across a spectrum of income levels. Our goal in offering these suites of services at the hub is to ensure that no matter where the patient presents, we are following their journey and endeavoring to ensure continuity of care. The collaboration that occurs between our HUB and our Specialty Pharmacy Partners, including



IOD (in-office dispensing) practices is noteworthy. Communication between all parties is always transparent, putting the patient first. Because of this collaboration, we have been able to innovate the way we conduct the open enrollment seasons, resulting in many more patients being able to afford their therapy.

During a recent third-party patient satisfaction survey conducted on our hub, 98% of practices and patients were very or completely satisfied with the myBeiGene® patient support program; and 96% felt their Oncology Nurse Advocate was knowledgeable, understood questions or issues they had, and clearly communicated and provided information or resources. In fact, we have found there are patients so dedicated to their Oncology Nurse Advocate, they are reluctant to transition away from the program.

With its dedicated and innovative patient support and distribution team, BeiGene constantly drives towards innovative solutions as the landscape continually shifts. These innovative solutions include:

- Revamping the voucher program to ensure ease of access and use for all HCPs
- Enhancing the copay portal, creating an electronic method for providers to enroll
- Pivoting and troubleshooting when processors failed, focusing on providing alternative options for HCPs to access therapy
- Enhancing the open enrollment process, allowing patients to quickly access foundation assistance

Specialty Pharmacy Business Model Acumen

BeiGene's collaboration with specialty pharmacies is multifaceted. In oncology, we work with specialty pharmacies in several settings: medically integrated dispensing pharmacies, 340B, and independent pharmacies. In our partnerships, we focus on disseminating emerging clinical evidence and specialized pharmacotherapy management strategies. We aim to tailor our approach to the needs of their patients, developing relevant tools that can be used when educating patients along their treatment journey. Our partnerships also work to uncover clinical insights, treatment patterns, and adherence patterns through collaborative real-world evidence (RWE) research projects. An example of this is a research collaboration with large integrated academic health care center's specialty pharmacy on a RWE research project, which demonstrated that CLL/SLL therapy initiation at specialty pharmacies may increase treatment adherence rates.

BeiGene's support of Community Oncology and IOD practices was recently recognized by the third-party organization Health Industries Research (HIRC), which gave BeiGene its highest score for quality of support offerings and field support, which includes Key Account Managers, Medical Liaisons, and Reimbursement Managers.

BeiGene is a proud active member of NASP by sitting on the Board of Directors and participating on multiple committees. BeiGene continues to partner and align in grassroots advocacy and policy efforts with NASP.



Community Involvement

BeiGene is committed to supporting our communities and making a positive impact on the world. Our core value is "patients first." We work with cancer patient communities globally to learn from patients and to partner with them to help improve health outcomes and access by identifying and addressing unmet patient needs. Our focus on patients and commitment to community involvement is exemplified by the following:

- The company launched the BeiGene Foundation in 2023 as an independent 501(c)(3) nonprofit organization to provide grants to charitable organizations aligned with the Foundation's mission. The Foundation provides funding to support charitable, community-engaged programs in three strategic areas: access to equitable cancer healthcare, community engagement, and disaster response.
- In 2023 the BeiGene Foundation launched a first of its kind, three-year global partnership with the Max Foundation to help people living with CLL in 29 low- and middle-income countries have free access to BRUKINSA® (zanubrutinib).
- With the knowledge that nearly 1 in 4 cancer patients live with depression and up to 20% are at risk for clinically significant anxiety, BeiGene launched the global "Talk About It" program to amplify the underserved intersection of cancer care and mental health to help improve outcomes for cancer patients.
- To support blood cancer patients, BeiGene is the new three-year national Presenting Sponsor for Survivorship and Hope of the Leukemia and Lymphoma Society's (LLS) Light the Night program as of 2024. In 2023, BeiGene was actively engaged in Light the Night with 239 colleagues joining 25 teams to raise funding for blood cancer research and patient resources through LLS.
- To advance the evolving U.S. cancer policy landscape and support efforts to improve patient access, BeiGene is a founding and ongoing sponsor of the CLL Society's Policy Institute.
- BeiGene serves on several Friends of Cancer Research working groups to advance the use of Real-World Data and Real-World Evidence in regulatory decision-making, along with inputting into the establishment of enrollment goals for racial and ethnic populations in clinical trials to inform future guidance needs and current thinking.
- BeiGene regularly convenes patient advocates and organizations through the BeiGene Patient Advocacy Council. In its fourth year, the council engages members in bi-directional insight sharing around access barriers for patients and advises Beigene on educational and programmatic needs of the cancer community.
- BeiGene is receiving the 2024 Lymphoma Research Foundation Corporate Leadership Award for our work with the patient community and leadership in cancer and mental health.